Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel
OTCMKTS:HYPMY

Hypermarcas Q4 2024 Earnings Report

Hypermarcas logo
$4.21 +0.10 (+2.38%)
As of 06/29/2026 02:55 PM Eastern
ProfileEarnings HistoryForecast

Hypermarcas EPS Results

Actual EPS
$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hypermarcas Revenue Results

Actual Revenue
$258.56 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hypermarcas Announcement Details

Quarter
Q4 2024
Date
3/20/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Hypermarcas' next earnings date is estimated for Wednesday, August 5, 2026, based on past reporting schedules.

Conference Call Resources

Hypermarcas Earnings Headlines

Hypera SA ADR (HYPMY)
May 24, 2026  |  investing.comhttps://www.investing.com/equities/hypermarcas-sa-financial-summary
Hypera S.A. (HYPMY) Q3 2025 Earnings Call Transcript
October 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4834950-hypera-s-a-hypmy-q3-2025-earnings-call-transcript
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.tc pixel
 |  Behind the Markets (Ad)
Brazil's Hypera announces new majority stakeholder group
July 7, 2025  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/brazils-hypera-announces-new-majority-stakeholder-group-2025-07-07/
Hypera S.A. (HYPMY) Stock Price, Quote, News & Analysis - Seeking Alpha
June 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/HYPMY
Hypera S.A. credit rating downgraded due to increased leverage
April 9, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/hypera-sa-credit-rating-downgraded-due-to-increased-leverage-93CH-3977909
See More Hypermarcas Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hypermarcas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hypermarcas and other key companies, straight to your email.

About Hypermarcas

Hypermarcas (OTCMKTS:HYPMY) S.A. is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products. Its pharmaceutical lineup includes analgesics, anti-inflammatories, vitamins and dermatological preparations, while its consumer goods segment encompasses shampoos, soaps, lotions and oral hygiene items under multiple local brands.

Primarily focused on the domestic Brazilian market, Hypermarcas has also extended its reach into other Latin American countries via export partnerships and regional distributors. Over the years, the company has grown through acquisitions of smaller domestic drugmakers and consolidation of well-known local brands. Detailed executive leadership information is not widely available in public sources.

View Hypermarcas Profile
Earnings Tools